FindMyKOL

Yzhar Charuzi, MD

Basic profile

Cedars-Sinai Medical Center

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionLos Angeles, CA · WestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Yzhar Charuzi is a Cardiology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 49 publications with 1,882 citations (h-index 18).

Overview

Scholarship

indexed output and impact (OpenAlex)
49publications

Publications indexed by OpenAlex. Counts exclude supporting files.

1,882citations

Citations across these publications.

18h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • E.R. Squibb & Sons, L.L.C.
    Program year20253 payments
    $244
  • BridgeBio Pharma, Inc.
    Program year20251 payment
    $167
  • GENZYME CORPORATION
    Program year20251 payment
    $135
All 19 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    89.1%
    Beta blocker23%
    Carvedilol62%Metoprolol Tartrate29%Atenolol9%
    Part D<11 patients
    Statin17.3%
    Atorvastatin Calcium70%Rosuvastatin Calcium22%Simvastatin9%
    Part D<11 patients

    + 9 more classes in this area

  • Blood & clotting

    10.9%
    P2Y12 inhibitor5.5%
    Clopidogrel71%Brilinta29%
    Part D<11 patients
    Factor Xa inhibitor3.3%
    Eliquis100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”